Medigus: Polyrizon to Test its Product Candidate for Protection Against the Highly Transmissible Corona Virus Omicron Variant
December 23 2021 - 9:20AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies and
electric vehicle and charging solutions, today announced that
Polyrizon Ltd., a privately held company which Medigus owns 35.86%
of its share capital, will evaluate the viral infection prophylaxis
effect of its innovative product candidate against the Omicron
variant of the coronavirus (lineage B.1.1.529), in-vitro. This
study follows recent pre-clinical studies showed strong potential
against human coronavirus 229E and influenza virus infection.
The Omicron variant is rapidly spreading a
variant of SARS-CoV-2, demonstrating an unusually high number of
novel mutations, affecting the spike protein targeted by most
COVID-19 vaccines and classified as a Variant of Concern (VOC) by
the center for disease control and prevention (CDC).
Polyrizon is planning to assess the protection
effect of its Capture and Contain (C&C™) platform against the
recently reported emerged variant. The study is planned to begin in
Q1 2022 in collaboration with Prof. Fabio Sonvico from the
Department of Food and Drug Science of Parma University, Italy.
The frequently emerging new highly contagious
COVID-19 variants highlights the need for prevention solutions to
reduce the infection and transmission of these viruses. Polyrizon’s
C&C™ platform is a prevention-focused approach that when
combined with vaccination, social distancing, hygiene practices and
mask usage should further decrease the risk of infection.
In an ongoing pre-clinical studies Polyrizon
product is tested for Protection against the high transmissible
corona viruses, the Delta variant lineage B.1.617.2 and the Gamma
variant lineage P.1.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technology company focused on innovative growth partnerships,
mainly in advanced medical solutions, digital commerce and electric
vehicle markets. Medigus' affiliations in the medical solutions
arena include ownership in Polyrizon Ltd. and ownership in industry
4.0 company, ScoutCam Inc. The Company’s affiliates in digital
commerce include Gix Internet Ltd., Jeffs' Brands Ltd. and Eventer
Technologies Ltd. In the electric vehicle market, Charging Robotics
Ltd. and Revoltz Ltd. are also part of the Company’s portfolio of
technology solution providers. To learn more about Medigus’
advanced technologies, please
visit http://www.medigus.com/.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. Because such statements deal with
future events and are based on Medigus’ current expectations, they
are subject to various risks and uncertainties, and actual results,
performance or achievements of Medigus could differ materially from
those described in or implied by the statements in this press
release. More specifically, Medigus uses forward looking statements
when describing Polyrizon’s upcoming study in connection
with the Omicron variant.
The forward-looking statements contained or
implied in this press release are subject to other risks and
uncertainties, including those discussed in any filings with the
Securities and Exchange Commission. Except as otherwise required by
law, Medigus undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. References and links to websites have been
provided as a convenience, and the information contained on such
websites is not incorporated by reference into this press release.
Medigus is not responsible for the contents of third-party
website.
Company Contact:
Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
Investor Relations Contact:
Miri Segal
CEO
MS-IR LLC
+1-917-607-8654
msegal@ms-ir.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024